
NASDAQHealthcareBiotechnology
ข้อมูลล่าสุด
US$554.73
−US$4.37 · -0.78%
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
ราคาปิดก่อนหน้า
US$554.73
−US$4.37 · -0.78%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
ช่วงราคารายวัน
ปัจจุบัน US$554.73
ช่วง 52 สัปดาห์
ปัจจุบัน US$554.73
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ซื้อ
มูลค่า
91
มูลค่าน่าสนใจมาก
ความเชื่อมั่น
66
เชิงบวก
ความเสี่ยง
19
ความเสี่ยงต่ำ
โมเมนตัม
52
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
ช่วงราคารายวัน
ปัจจุบัน US$554.73
ช่วง 52 สัปดาห์
ปัจจุบัน US$554.73
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 3.18B USD | 2.88B USD | 2.33B USD | 1.94B USD | 1.69B USD |
| ต้นทุนสินค้าขาย | 384.4M USD | 309.7M USD | 257.5M USD | 146.7M USD | 122.5M USD |
| กำไรขั้นต้น | 2.8B USD | 2.57B USD | 2.07B USD | 1.79B USD | 1.56B USD |
| การวิจัยและพัฒนา | 550M USD | 481M USD | 408M USD | 322.9M USD | 540.1M USD |
| การขาย ทั่วไป และธุรการ | 731.1M USD | 638.6M USD | 477.1M USD | 487M USD | 467M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 1.28B USD | 1.19B USD | 885.1M USD | 809.9M USD | 1.01B USD |
| รายได้ดอกเบี้ย | 192M USD | 199.1M USD | 162.7M USD | 45.2M USD | 16.7M USD |
| ดอกเบี้ยจ่าย | 19.5M USD | 42.9M USD | 59.3M USD | 32.4M USD | 18.6M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 85.6M USD | 72.5M USD | 53.2M USD | 51.3M USD | 49.9M USD |
| รายได้จากการดำเนินงาน | 1.52B USD | 1.38B USD | 1.18B USD | 979.7M USD | 555.9M USD |
| รายได้สุทธิ | 1.33B USD | 1.2B USD | 984.8M USD | 727.3M USD | 475.8M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 22 พ.ย. 2569.
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
iShares Core S&P Mid-Cap ETFIJH857.28M0.75%115.06B USD0.05%US$68.60-2.68%
Vanguard Morningstar Total Stock Market ETFVTI643.93M0.04%689.3B USD0.03%US$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB575.74M0.32%78.7B USD0.03%US$270.68-2.56%
Vanguard Extended Market ETFVXF291.23M0.31%30.2B USD0.05%US$211.44-3.21%
Vanguard Morningstar Small-Cap Value ETFVBR187.11M0.28%37.1B USD0.05%US$231.38-2.02%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY179.54M0.73%24.52B USD0.23%US$626.03-2.64%
iShares Biotechnology ETFIBB177.99M1.70%10.53B USD0.44%US$199.54-2.05%
Invesco S&P MidCap Quality ETFXMHQ167.72M3.03%5.4B USD0.30%US$111.72-2.21%
iShares Core S&P Mid-Cap ETFIJH
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Extended Market ETFVXF
Vanguard Morningstar Small-Cap Value ETFVBR
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
iShares Biotechnology ETFIBB
Invesco S&P MidCap Quality ETFXMHQเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน